Portal de Periódicos da CAPES

Fibrosing Cholestatic Hepatitis in HIV/HCV Co-Infected Transplant Patients—Usefulness of Early Markers After Liver Transplantation

2011; Elsevier BV; Volume: 11; Issue: 8 Linguagem: Inglês

10.1111/j.1600-6143.2011.03608.x

1600-6143

Térésa Antonini, Mylène Sebagh, Anne‐Marie Roque‐Afonso, Elina Teicher, Benjamín Roche, Rodolphe Sobesky, Audrey Coilly, P. Vaghefi, René Adam, Daniel Vittecoq, D. Castaing, Didier Samuel, Jean‐Charles Duclos‐Vallée,

Hepatitis C virus research

We characterized fibrosing cholestatic hepatitis (FCH) in a large cohort of HIV/HCV co-infected patients. Between 1999 and 2008, 59 HIV infected patients were transplanted for end-stage liver disease due to HCV. Eleven patients (19%) developed FCH within a mean period of 7 months [2-27] after liver transplantation (LT). At Week 1 post-LT, the mean HCV viral load was higher in the FCH group: 6.13 log(10) IU/mL ± 1.30 versus 4.9 log(10) IU/mL ± 1.78 in the non-FCH group, p = 0.05. At the onset of acute hepatitis after LT, activity was moderate to severe in 8/11 HIV+/HCV+ patients with FCH (73%) versus 13/28 (46%) HIV+/HCV+ non-FCH (p = 0.007) patients. A complete virological response to anti-HCV therapy was observed in 2/11 (18%) patients. Survival differed significantly between the two groups (at 3 years, 67% in non-FCH patients versus 15% in FCH patients, p = 0.004). An early diagnosis of FCH may be suggested by the presence of marked disease activity when acute hepatitis is diagnosed and when a high viral load is present. The initiation of anti-HCV therapy should be considered at this point.